Lancet respirat: Phase 3 clinical trial of Tongji University reveals the efficacy of icotinib in EGFR-mutant advanced NSCLC

Icotinib provides survival benefits for patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer ( NSCLC )
.

The EVIDENCE trial is a multi-center, randomized, open-label Phase 3 study conducted in 29 hospitals in China.

NSCLC

The study recruited 18-70-year-old patients with histologically confirmed stage II-IIIA NSCLC who underwent complete tumor resection 8 weeks before randomization, and were tested for activation on exon 19 or 21 of the EGFR gene Mutation
.

The subjects were randomly (1:1) divided into two groups and received oral icotinib (125 mg, 3 times/day) for 2 years, or intravenous chemotherapy (adenocarcinoma or squamous cell carcinoma: Vinorelbine [25 mg /m ² , day 1 and 8] combined with cisplatin [75mg/m ² , day 1 of each course]; non-squamous cell carcinoma: pemetrexed [500 mg/m ² ] combined with cisplatin [75 mg /m ² , the first day of every 3 weeks])

^{2 2 2 2}

Survival prognosis

Survival prognosis

From June 8, 2015 to August 2, 2019, 322 patients were randomly assigned to the icotinib group or the chemotherapy group (151 groups each); 151 patients in the icotinib group and 132 patients in the chemotherapy group Be included in the full analysis cohort
.

The median follow-up time for the full analysis cohort was 24.

Forty of the 151 patients in the icotinib group (26%) and 58 of the 132 patients in the chemotherapy group (44%) had disease recurrence or death

Two (1%) and 19 (14%) patients in the icotinib group and the chemotherapy group had serious treatment-related adverse reactions
.

No interstitial pneumonia or treatment-related deaths were observed in either group

In summary, the results of this analysis show that in patients with stage II-IIIA NSCLC with EGFR mutations after complete tumor resection, compared with chemotherapy, icotinib significantly improves disease-free survival and has better Tolerance

In patients with stage II-IIIA NSCLC with EGFR mutations after complete tumor resection, icotinib significantly improved disease-free survival compared with chemotherapy and has better tolerance to EGFR mutations after complete tumor resection In patients with stage II-IIIA NSCLC, compared with chemotherapy, icotinib significantly improves disease-free survival and is better tolerated

Original source:

Original source:

Jianxing, et al.

Leave a message here